Stressgen's attack on HPV
Human papillomavirus (HPV) is a difficult target because it can lie dormant and replicates at low levels in the squamous epithelium. Also, there are more than 100 HPV genotypes, which makes development of a broad-acting therapeutic very difficult.
However, that hasn't stopped companies from seeking to develop drugs to prevent and treat HPV, which is associated with genital warts, cervical cancer and other conditions. Last week, Stressgen Biotechnologies Corp.